SEC Form 424B3 filed by Cosmos Health Inc.

12/18/24 8:35:57 AM ET

$COSM

Other Pharmaceuticals

Health Care

Get the next $COSM alert in real time by email

Unavailable

Get the next $COSM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$COSM

Date	Price Target	Rating	Analyst

More analyst ratings

$COSM
Leadership Updates

Live Leadership Updates

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology
CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.He is a medical specialist in onc
12/26/24 1:30:00 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share
THESSALONIKI, GREECE / ACCESSWIRE / November 21, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today provided a business update and reported financial results for the third quarter and nine months ended September 30, 2023.Third Quarter 2023 Financial HighlightsRevenues increased to $12.8 million from $12.0 million in Q3 2022, largely due to increased sales attributable to the logistics distribution business, which expanded
11/21/23 9:00:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Appoints Big 4 Accounting Firm KPMG as Auditor
CHICAGO, IL / ACCESSWIRE / August 8, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today the engagement of KPMG Certified Auditors S.A. ("KPMG") as the Company's independent registered public accounting firm, effective August 7, 2023. KPMG replaces the Company's former auditor, Armanino LLP.The appointment of KPMG was made by the Cosmos Health Board of Directors at the recommendation of its Audit Committee. The decision to change auditors was not the result of any disagreement between the Company
8/8/23 9:20:00 AM ET
$COSM
Other Pharmaceuticals
Health Care

$COSM
Financials

Live finance-specific insights

Cosmos Health Issues Letter to Shareholders
CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.Dear Cosmos Health Shareholders,It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support. We have achieved many positive milestone
11/12/24 12:01:41 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform
CHICAGO, IL / ACCESSWIRE / March 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the initiation of the development of Cloudscreen 2.0, the new iteration of its groundbreaking Artificial Intelligence (AI) drug repurposing platform.As previously announced, on January 23, 2024, Cosmos Health completed the acquisition of Cloudscreen. Building on the success of its predecessor, Cloudscreen 2.0 represents a sign
3/21/24 9:45:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market
CHICAGO, IL / ACCESSWIRE / January 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has successfully completed the acquisition of Cloudscreen®, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023.Cloudscreen is a multimodal platform specialized in drug repurposing, a process that involves uncovering new tar
1/23/24 1:05:00 PM ET
$COSM
Other Pharmaceuticals
Health Care

$COSM
Press Releases

Fastest customizable press release news feed in the world

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries
CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a distribution agreement with Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax") to distribute Virax-branded Avian Influenza Virus ("AIV") Real-Time PCR Kits across various major European markets and certain Gulf Cooperation Council (GCC) countries.Specifically, Cosmos Health gains exclusive rights t
1/13/25 9:20:00 AM ET
$COSM
$VRAX
Other Pharmaceuticals
Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology
CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.He is a medical specialist in onc
12/26/24 1:30:00 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000
CHICAGO, IL / ACCESSWIRE / December 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, and CFO, George Terzis, increased their stake in the Company by approximately 343,122 common shares, valued at $200,000, based on the closing share price on Friday, December 20, 2024.Specifically, Mr. Siokas increased his stake by approximately 257,334 common shares, valued at $150,000, while Mr.
12/23/24 9:25:00 AM ET
$COSM
Other Pharmaceuticals
Health Care

SEC Form 424B3 filed by Cosmos Health Inc.

Chat with this insight

Recent Analyst Ratings for
$COSM

$COSM
Leadership Updates

Live Leadership Updates

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

Cosmos Health Appoints Big 4 Accounting Firm KPMG as Auditor

$COSM
Financials

Live finance-specific insights

Cosmos Health Issues Letter to Shareholders

Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform

Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market

$COSM
Press Releases

Fastest customizable press release news feed in the world

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000

$COSM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

$COSM
SEC Filings

$COSM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

SEC Form SC 13G filed by Cosmos Health Inc.

SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

Amendment: SEC Form S-1/A filed by Cosmos Health Inc.

Amendment: SEC Form S-1/A filed by Cosmos Health Inc.

Amendment: SEC Form S-1/A filed by Cosmos Health Inc.

Chief Executive Officer Siokas Grigorios bought $40,000 worth of shares (47,904 units at $0.83), increasing direct ownership by 1% to 4,135,631 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $50,000 worth of shares (62,500 units at $0.80), increasing direct ownership by 2% to 4,087,727 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $60,000 worth of shares (87,247 units at $0.69), increasing direct ownership by 2% to 4,025,227 units (SEC Form 4)

$COSM
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Siokas Grigorios bought $40,000 worth of shares (47,904 units at $0.83), increasing direct ownership by 1% to 4,135,631 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $50,000 worth of shares (62,500 units at $0.80), increasing direct ownership by 2% to 4,087,727 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $60,000 worth of shares (87,247 units at $0.69), increasing direct ownership by 2% to 4,025,227 units (SEC Form 4)

SEC Form 424B3 filed by Cosmos Health Inc.

Chat with this insight

Recent Analyst Ratings for $COSM

$COSM Leadership Updates

Live Leadership Updates

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

Cosmos Health Appoints Big 4 Accounting Firm KPMG as Auditor

$COSM Financials

Live finance-specific insights

Cosmos Health Issues Letter to Shareholders

Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform

Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market

$COSM Press Releases

Fastest customizable press release news feed in the world

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000

$COSM Large Ownership Changes

This live feed shows all institutional transactions in real time.

$COSM SEC Filings

$COSM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

SEC Form SC 13G filed by Cosmos Health Inc.

SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

Amendment: SEC Form S-1/A filed by Cosmos Health Inc.

Amendment: SEC Form S-1/A filed by Cosmos Health Inc.

Amendment: SEC Form S-1/A filed by Cosmos Health Inc.

Chief Executive Officer Siokas Grigorios bought $40,000 worth of shares (47,904 units at $0.83), increasing direct ownership by 1% to 4,135,631 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $50,000 worth of shares (62,500 units at $0.80), increasing direct ownership by 2% to 4,087,727 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $60,000 worth of shares (87,247 units at $0.69), increasing direct ownership by 2% to 4,025,227 units (SEC Form 4)

$COSM Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Siokas Grigorios bought $40,000 worth of shares (47,904 units at $0.83), increasing direct ownership by 1% to 4,135,631 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $50,000 worth of shares (62,500 units at $0.80), increasing direct ownership by 2% to 4,087,727 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $60,000 worth of shares (87,247 units at $0.69), increasing direct ownership by 2% to 4,025,227 units (SEC Form 4)

Recent Analyst Ratings for
$COSM

$COSM
Leadership Updates

$COSM
Financials

$COSM
Press Releases

$COSM
Large Ownership Changes

$COSM
SEC Filings

$COSM
Insider Trading

$COSM
Insider Purchases